Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annual Moderate and Severe Exacerbations

被引：0
|
作者：
Ismaila, A. S. [1 ]
Haeussler, K. [2 ]
Czira, A. [3 ]
Youn, J. [4 ]
Malmenas, M. [5 ]
Risebrough, N. [6 ]
Agarwal, J. [7 ]
Nassim, M.
Sharma, R. [3 ]
Compton, C. [3 ]
Vogelmeier, C. F. [8 ]
Halpin, D. M. G. [9 ]
机构：
[1] GlaxoSmithKline, R&D Global Med, Collegeville, PA USA
[2] ICON plc, Munich, Germany
[3] GlaxoSmithKline, R&D Global Med, Brentford, England
[4] ICON plc, London, England
[5] ICON plc, Stockholm, Sweden
[6] ICON plc, Burlington, ON, Canada
[7] ICON plc, Bangalore, Karnataka, India
[8] Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, Dept Med, Pulm & Crit Care Med, Marburg, Germany
[9] Univ Exeter, Univ Exeter Med Sch, Coll Med & Hlth, Exeter, Devon, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2022年 / 205卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1454
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of Age on Efficacy and Safety of Multiple Inhaler Triple Therapy with Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease
    Soule, T.
    Caveney, S.
    Tombs, L.
    Boucot, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [22] Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system
    Balmaceda, Carlos
    Espinoza, Manuel A.
    Abbott, Tomas
    Peters, Anne
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (05) : 743 - 751
  • [23] Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials
    Li Wang
    Chun-juan Zhai
    Yao Liu
    Yi Liu
    Shu-juan Jiang
    Clinical Drug Investigation, 2016, 36 : 865 - 875
  • [24] FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL VS OPEN TRIPLE THERAPY FOR TREATING SEVERE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM A BRAZILIAN PUBLIC HEALTHCARE PERSPECTIVE: A BUDGET IMPACT ANALYSIS
    Araujo, M.
    Bernardino, G.
    Tanaka, S. Y.
    VALUE IN HEALTH, 2024, 27 (06) : S151 - S151
  • [25] Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials
    Wang, Li
    Zhai, Chun-juan
    Liu, Yao
    Liu, Yi
    Jiang, Shu-juan
    CLINICAL DRUG INVESTIGATION, 2016, 36 (11) : 865 - 875
  • [26] Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials
    Zhai, Chunjuan
    Wang, Fen
    Xu, Ruie
    Sun, Xia
    Ma, Wenbin
    Wang, Li
    POSTGRADUATE MEDICAL JOURNAL, 2024, 100 (1188) : 721 - 729
  • [27] Evaluation of comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs
    Zhu, He
    Lei, Jiahui
    Gao, Fan
    Guo, Yingjie
    Zhao, Limin
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [28] Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis
    Ismaila, A. S.
    Czira, A.
    Haeussler, K.
    Tongbram, V.
    Malmenas, M.
    Agarwal, J.
    Nassim, M.
    Shen, Y.
    Duarte, M.
    Compton, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [29] Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease
    Calzetta, Luigino
    Rogliani, Paola
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (12) : 1273 - 1283
  • [30] Cost-effectiveness of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) Versus Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) to Treat COPD Based on Mortality Risk Reduction From a Matching-adjusted Indirect Treatment Comparison
    Parsekar, K.
    Pandey, S.
    Tansey-Dwyer, D.
    Marshall, J.
    Rustignoli, I.
    Pollack, M.
    Singh, B.
    Ouwens, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
12345